BRCA1 and breast carcinoma: For instance, poly ADP‐ribose polymerase (PARP) inhibitors are effective drugs against breast cancer patients who have lost HR capability due to the mutations of BRCA1/2 but simultaneously with enhanced activity of PARP.38, 39